公开(公告)号：US20240255524A1

公开(公告)日：2024-08-01

申请号：US18566223

申请日：2022-06-14

申请人： SomaLogic Operating Co., Inc.

发明人： Laura Sampson ,  Missy Simpson ,  Yolanda Hagar ,  Rachel Marie Ostroff

IPC分类号： G01N33/68

CPC分类号： G01N33/6887 ,  G01N33/6893 ,  G01N2333/78 ,  G01N2800/347

摘要： The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of renal insufficiency within a specified timeframe, for example 4 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of renal insufficiency within 4 years. In another aspect, methods are provided for evaluating risk of renal insufficiency within 4 years in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 8.

公开(公告)号：US20240210405A1

公开(公告)日：2024-06-27

申请号：US17914101

申请日：2021-03-22

申请人： Nordic Bioscience A/S

发明人： Nicholas Willumsen ,  Jeppe Thorlacius-Ussing

IPC分类号： G01N33/574 ,  C07K16/18 ,  G01N33/68

CPC分类号： G01N33/57488 ,  C07K16/18 ,  G01N33/6887 ,  C07K2317/34 ,  G01N2333/78 ,  G01N2470/10

摘要： The present invention relates to monoclonal antibodies that target collagen type XIX, and to immunoassays and kits employing the antibodies. The assays of the invention can be used in the diagnosis and monitoring of cancer.

公开(公告)号：US11885800B2

公开(公告)日：2024-01-30

申请号：US17037162

申请日：2020-09-29

申请人： IMRA America, Inc.

发明人： Bing Liu ,  Matthew L. Elani ,  Alison R. Garrett

IPC分类号： G01N33/543 ,  G01N27/74 ,  G01N33/68 ,  G01N33/76 ,  G01N35/00

CPC分类号： G01N33/54333 ,  G01N27/745 ,  G01N33/54326 ,  G01N33/6887 ,  G01N33/76 ,  B01L2200/025 ,  G01N35/0098

摘要： A system includes an apparatus having at least one permanent magnet and at least one magnetic field sensor at a pole of the at least one permanent magnet and configured to be positioned relative to a surface of a membrane containing immobilized magnetic particles selectively bound to an analyte such that the magnetic particles are magnetized by the at least one permanent magnet. The system further includes a stage configured to move at least one of the apparatus and the membrane relative to one another with an oscillatory movement parallel to the surface of the membrane, at least one controller configured to control the oscillatory movement, and a data acquisition unit configured to receive signals from the at least one magnetic field sensor and the at least one controller method.

公开(公告)号：US20240003874A1

公开(公告)日：2024-01-04

申请号：US18340791

申请日：2023-06-23

申请人： Quidel Cardiovascular Inc.

发明人： Jonathan GARY ,  Scott RONGEY ,  James POWELL

IPC分类号： G01N33/543 ,  C07K16/18 ,  G16H40/63 ,  G01N33/558

CPC分类号： G01N33/54386 ,  C07K16/18 ,  G01N33/54393 ,  G16H40/63 ,  G01N33/558 ,  G01N2333/4712 ,  G01N33/6887

摘要： The present invention relates to compositions and methods use in designing immunoassay controls. In various aspects, the invention provides synthetic peptides comprising the sequence CPRRPYIL (SEQ ID NO: 1) or an analog thereof; ELAGLGFAELQC (SEQ ID NO: 4) or an analog thereof; and CDWRKNIDAL (SEQ ID NO: 8) or an analog thereof; specific binding reagents that bind to a CPRRPYIL (SEQ ID NO: 1), ELAGLGFAELQC (SEQ ID NO: 4) or CDWRKNIDAL (SEQ ID NO: 8) peptide; methods of producing such reagents; and assays utilizing such reagents to provide assay controls signals that are unrelated to the measurement of the analyte or analytes of interest in that no reagents used in the analyte assay(s) contribute to the control signal.

公开(公告)号：US20230349921A1

公开(公告)日：2023-11-02

申请号：US18173604

申请日：2023-02-23

申请人： Shriners Hospitals for Children

发明人： William A. Horton ,  Gregory P. Lunstrum ,  Ryan F. Coghlan ,  Jon A. Oberdorf

IPC分类号： G01N33/68 ,  G01N33/50 ,  G01N33/543 ,  G01N33/566 ,  C07K14/78 ,  G01N33/535 ,  G01N33/574

CPC分类号： G01N33/6887 ,  C07K14/78 ,  G01N33/5029 ,  G01N33/5044 ,  G01N33/5082 ,  G01N33/535 ,  G01N33/54306 ,  G01N33/566 ,  G01N33/57488 ,  A61K38/00 ,  G01N2800/10 ,  G01N2800/52 ,  G01N2800/60

摘要： The present invention provides methods for determining bone growth velocity comprising: (a) measuring an amount of a collagen X marker in a sample obtained from a subject in need thereof; and (b) comparing the amount of collagen X marker measured in step (a) with a collagen X marker standard curve, wherein the amount of collagen X marker is measured using at least two reagents. In an embodiment, there is at least one capture reagent and at least one detection reagent. In a preferred embodiment for measuring CXM, the capture reagent is the aptamer SOMA1 and the detection reagent is the monoclonal antibody mAb X34. The present invention further provides methods for treating diseases, disorders or conditions comprising receiving an identification of an amount of CXM in a sample, wherein the amount of CXM has been identified using a combination of SOMA1 and mAb X34 as CXM-binding reagents, and administering a treatment in light of the amount of CXM in the sample.

公开(公告)号：US20230348857A1

公开(公告)日：2023-11-02

申请号：US18338437

申请日：2023-06-21

申请人： Xintela AB

发明人： Evy Lundgren Åkerlund ,  Katarzyna Chmielarska Masoumi

IPC分类号： C12N5/077 ,  C12N5/00 ,  C12Q1/6851 ,  G01N33/68

CPC分类号： C12N5/0655 ,  C12N5/0018 ,  C12N5/0068 ,  C12Q1/6851 ,  G01N33/6887 ,  C12N2513/00 ,  G01N2333/70546 ,  C12N2501/58 ,  C12N2500/38 ,  C12N2501/585

摘要： The present invention relates to methods that are based on expression of integrin alpha10 and integrin alpha11 on chondrocytes, used for determining purity, quality, degree of chondrocytic identity, chondrocytic potency, and/or degree of chondrocytic phenotype of a composition comprising chondrocytes, as well as for isolating and enriching a population of high quality chondrocytes and controlling culturing and expanding of high quality chondrocytes. The present invention relates also to composition comprising chondrocytes.

公开(公告)号：US11747328B2

公开(公告)日：2023-09-05

申请号：US16169158

申请日：2018-10-24

申请人： BIOMERIEUX

发明人： Sylvie Cheucle ,  Laure Marillet ,  Aurélie Thollet

IPC分类号： G01N33/543 ,  G01N33/68 ,  G16B40/10 ,  G16B40/00

CPC分类号： G01N33/543 ,  G01N33/6887 ,  G16B40/10 ,  G01N2333/47 ,  G01N2333/4706 ,  G01N2333/75 ,  G16B40/00

摘要： A method of measuring an analyte amount in a whole blood sample, including (i) measuring the haematocrit level of the whole blood sample; (ii) measuring an analyte amount directly in the whole blood sample; and (iii) calculating a corrected analyte amount according to relation DP=Pa(DST, DH), where Dp, is the corrected analyte amount, DST is the measured analyte amount, DH is the measured haematocrit level, and Pa is a non-constant polynomial of a degree greater than or equal to 1 having as indeterminate values the measured analyte amount, DST, and the measured haematocrit level, DH, and having its polynomial coefficients depending on the analyte.

公开(公告)号：US20230266339A1

公开(公告)日：2023-08-24

申请号：US18040497

申请日：2020-11-26

申请人： NANJING UNIVERSITY OF CHINESE MEDICINE

发明人： Rui LIU ,  Shuo CAI ,  Mengtong JIANG ,  Kexuan ZHAO ,  Jinao DUAN

IPC分类号： G01N33/68 ,  C07K14/78 ,  G01N30/72 ,  G01N30/88

CPC分类号： G01N33/6887 ,  C07K14/78 ,  G01N30/88 ,  G01N30/7233 ,  G01N33/6848 ,  G01N2030/8831 ,  G01N2333/944

摘要： Disclosed are a deer-derived specific peptide and a detection method therefor; by screening through a large number of experiments, a ratio of relative contents of two deer-derived peptides is determined, and a graph is drawn by using a proportion of a deer antler gelatin in a mixed gelatin as an abscissa and using a value of Apeptide 1/Apeptide 2 as an ordinate; the proportion of the deer antler gelatin is linear with Apeptide 1/Apeptide 2 as a standard curve equation to distinguish a deer hide gelatin from the deer antler gelatin; the method can be used for distinguishing the deer antler gelatin from the deer hide gelatin, and controlling the quality; a defect in the prior art that the deer antler gelatin and the deer hide gelatin are difficult to distinguish in appearance, and are also difficult to distinguish by using a specific peptide fragment, is solved.

公开(公告)号：US11693013B2

公开(公告)日：2023-07-04

申请号：US16492590

申请日：2018-03-12

申请人： UCL Business Ltd.

发明人： Thomas Voit ,  Julie Dumonceaux ,  Virginie Mariot

IPC分类号： G01N33/68 ,  A61K38/17 ,  G01N33/74

CPC分类号： G01N33/6887 ,  A61K38/177 ,  G01N33/74 ,  G01N2800/52

摘要： The present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising: (a) determining a level of myostatin and/or activin type II receptor (ActRII) and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; and (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, the patient will respond to treatment.

公开(公告)号：US20230204600A1

公开(公告)日：2023-06-29

申请号：US18009632

申请日：2021-06-11

申请人： National Institute of Advanced Industrial Science and Technology

发明人： Tomoko WATANABE ,  Hiroaki TATENO ,  Shuuji MAWARIBUCHI ,  Yoshikazu HARAMOTO

IPC分类号： G01N33/68

CPC分类号： G01N33/6887 ,  G01N2470/04

摘要： An object of the present invention is to provide a novel method that enables determination or evaluation of the undifferentiated state of human pluripotent stem cells simply, efficiently and non-invasively. The present invention provides a method for determining or evaluating the undifferentiated state of human pluripotent stem cells, comprising a step of detecting or measuring fibronectin in a culture supernatant of human pluripotent stem cells.